Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease

Current Opinion in Pharmacology

Volumn 33, Issue , 2017, Pages 64-69

  Deshwal, Soni ^a   Di Sante, Moises ^b   Di Lisa, Fabio ^a   Kaludercic, Nina ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; DRUG TARGETING; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIAC MUSCLE CELL; DRUG EFFECTS; METABOLISM; MITOCHONDRION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MYOCYTES, CARDIAC;

EID: 85019455437     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2017.04.003     Document Type: Review

References (47)

1. Kaludercic, N., Mialet-Perez, J., Paolocci, N., Parini, A., Di Lisa, F., Monoamine oxidases as sources of oxidants in the heart. J. Mol. Cell. Cardiol. 73 (2014), 34–42.
2. Edmondson, D.E., Binda, C., Mattevi, A., The FAD binding sites of human monoamine oxidases A and B. Neurotoxicology 25 (2004), 63–72.
3. Kaludercic, N., Carpi, A., Menabo, R., Di Lisa, F., Paolocci, N., Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim. Biophys. Acta 1813 (2011), 1323–1332.
4. Youdim, M.B., Edmondson, D., Tipton, K.F., The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7 (2006), 295–309.
5. 5• Dao, V.T., Casas, A.I., Maghzal, G.J., Seredenina, T., Kaludercic, N., Robledinos-Anton, N., Di Lisa, F., Stocker, R., Ghezzi, P., Jaquet, V., et al. Pharmacology and clinical drug candidates in redox medicine. Antioxid. Redox Signal. 23 (2015), 1113–1129 This review discusses the possibility of targeting the enzymatic sources of disease-relevant oxidative stress, rather than using antioxidants as therapeutic strategy. Pharmacological tools and their respective targets are reviewed in relation to disease.
6. Hauser, R.A., Li, R., Perez, A., Ren, X., Weintraub, D., Elm, J., Goudreau, J.L., Morgan, J.C., Fang, J.Y., Aminoff, M.J., et al. Longer duration of MAO-B inhibitor exposure is associated with less clinical decline in Parkinson's disease: an analysis of NET-PD LS1. J. Parkinson's Dis. 7.1 (2016), 117–127.
7. Fabbri, M., Rosa, M.M., Abreu, D., Ferreira, J.J., Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Neurodegener. Dis. Manag. 5 (2015), 481–496.
8. Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., de Ferranti, S., Despres, J.P., Fullerton, H.J., Howard, V.J., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–322.
9. 9• Casas, A.I., Dao, V.T., Daiber, A., Maghzal, G.J., Di Lisa, F., Kaludercic, N., Leach, S., Cuadrado, A., Jaquet, V., Seredenina, T., et al. Reactive oxygen-related diseases: therapeutic targets and emerging clinical indications. Antioxid. Redox Signal. 23 (2015), 1171–1185 This review covers the disease-relevant sources of ROS and discusses the reasons for the failure of chronic antioxidant therapies. It points out the importance of treating the disease-relevant ROS at the right moment, leaving the physiological ROS formation intact.
10. Hauptmann, N., Grimsby, J., Shih, J.C., Cadenas, E., The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch. Biochem. Biophys. 335 (1996), 295–304.
11. 2 in comparison to the mitochondrial respiratory chain. The Authors also show that MAO activity in this tissue is the major risk factor and predictor for the postoperative atrial fibrillation.
12. Bianchi, P., Kunduzova, O., Masini, E., Cambon, C., Bani, D., Raimondi, L., Seguelas, M.H., Nistri, S., Colucci, W., Leducq, N., et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 112 (2005), 3297–3305.
13. Pchejetski, D., Kunduzova, O., Dayon, A., Calise, D., Seguelas, M.H., Leducq, N., Seif, I., Parini, A., Cuvillier, O., Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ. Res. 100 (2007), 41–49.
14. Carpi, A., Menabo, R., Kaludercic, N., Pelicci, P., Di Lisa, F., Giorgio, M., The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. Biochim. Biophys. Acta 1787 (2009), 774–780.
15. 2 formation primarily in the mitochondria and that MAO-dependent ROS generation can directly target mitochondria to induce mitochondrial dysfunction. In addition, the Authors show for the first time that MAO-dependent aldehyde generation is able to induce mitochondrial dysfunction, ultimately leading to heart failure.
16. Kaludercic, N., Takimoto, E., Nagayama, T., Feng, N., Lai, E.W., Bedja, D., Chen, K., Gabrielson, K.L., Blakely, R.D., Shih, J.C., et al. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ. Res. 106 (2010), 193–202.
17. Umbarkar, P., Singh, S., Arkat, S., Bodhankar, S.L., Lohidasan, S., Sitasawad, S.L., Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy. Free Radic. Biol. Med. 87 (2015), 263–273.
18. Villeneuve, C., Guilbeau-Frugier, C., Sicard, P., Lairez, O., Ordener, C., Duparc, T., De Paulis, D., Couderc, B., Spreux-Varoquaux, O., Tortosa, F., et al. p53-PGC-1alpha pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid. Redox Signal. 18 (2013), 5–18.
19. 2 that, in turn, prevents TFEB translocation to the nucleus and lysosomal biogenesis.
20. Skowronska, M., Zielinska, M., Wojcik-Stanaszek, L., Ruszkiewicz, J., Milatovic, D., Aschner, M., Albrecht, J., Ammonia increases paracellular permeability of rat brain endothelial cells by a mechanism encompassing oxidative/nitrosative stress and activation of matrix metalloproteinases. J. Neurochem. 121 (2012), 125–134.
21. Zorov, D.B., Juhaszova, M., Sollott, S.J., Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev. 94 (2014), 909–950.
22. Inagaki, T., Akiyama, T., Du, C.K., Zhan, D.Y., Yoshimoto, M., Shirai, M., Monoamine oxidase-induced hydroxyl radical production and cardiomyocyte injury during myocardial ischemia-reperfusion in rats. Free Radic. Res. 50 (2016), 645–653.
23. Menazza, S., Blaauw, B., Tiepolo, T., Toniolo, L., Braghetta, P., Spolaore, B., Reggiani, C., Di Lisa, F., Bonaldo, P., Canton, M., Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. Hum. Mol. Genet. 19 (2010), 4207–4215.
24. Canton, M., Skyschally, A., Menabo, R., Boengler, K., Gres, P., Schulz, R., Haude, M., Erbel, R., Di Lisa, F., Heusch, G., Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur. Heart J. 27 (2006), 875–881.
25. Canton, M., Menazza, S., Sheeran, F.L., Polverino de Laureto, P., Di Lisa, F., Pepe, S., Oxidation of myofibrillar proteins in human heart failure. J. Am. Coll. Cardiol. 57 (2011), 300–309.
26. Coatrieux, C., Sanson, M., Negre-Salvayre, A., Parini, A., Hannun, Y., Itohara, S., Salvayre, R., Auge, N., MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. Free Radic. Biol. Med. 43 (2007), 80–89.
27. Di Lisa, F., Kaludercic, N., Carpi, A., Menabo, R., Giorgio, M., Mitochondria and vascular pathology. Pharmacol. Rep. 61 (2009), 123–130.
28. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res. 107 (2010), 1058–1070.
29. Sturza, A., Leisegang, M.S., Babelova, A., Schroder, K., Benkhoff, S., Loot, A.E., Fleming, I., Schulz, R., Muntean, D.M., Brandes, R.P., Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. Hypertension 62 (2013), 140–146.
30. Cai, H., Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc. Res. 68 (2005), 26–36.
31. Burgoyne, J.R., Madhani, M., Cuello, F., Charles, R.L., Brennan, J.P., Schroder, E., Browning, D.D., Eaton, P., Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 317 (2007), 1393–1397.
32. Zweier, J.L., Chen, C.A., Druhan, L.J., S-Glutathionylation reshapes our understanding of endothelial nitric oxide synthase uncoupling and nitric oxide/reactive oxygen species-mediated signaling. Antioxid. Redox Signal. 14 (2011), 1769–1775.
33. Li, H., Horke, S., Forstermann, U., Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 237 (2014), 208–219.
34. Stasch, J.P., Schmidt, P.M., Nedvetsky, P.I., Nedvetskaya, T.Y., HS, A.K., Meurer, S., Deile, M., Taye, A., Knorr, A., Lapp, H., et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Investig. 116 (2006), 2552–2561.
35. Sturza, A., Duicu, O.M., Vaduva, A., Danila, M.D., Noveanu, L., Varro, A., Muntean, D.M., Monoamine oxidases are novel sources of cardiovascular oxidative stress in experimental diabetes. Can. J. Physiol. Pharmacol. 93 (2015), 555–561.
36. Poon, C.C., Seto, S.W., Au, A.L., Zhang, Q., Li, R.W., Lee, W.Y., Leung, G.P., Kong, S.K., Yeung, J.H., Ngai, S.M., et al. Mitochondrial monoamine oxidase-A-mediated hydrogen peroxide generation enhances 5-hydroxytryptamine-induced contraction of rat basilar artery. Br. J. Pharmacol. 161 (2010), 1086–1098.
37. Lighezan, R., Sturza, A., Duicu, O.M., Ceausu, R.A., Vaduva, A., Gaspar, M., Feier, H., Vaida, M., Ivan, V., Lighezan, D., et al. Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease. Can. J. Physiol. Pharmacol. 94 (2016), 1040–1047.
38. Oblath, R.W., Griffith, G.C., The aminase oxidase inhibitors. Their current place in clinical medicine. Calif. Med. 93 (1960), 343–346.
39. Griffith, G.C., Amine oxidase inhibitors; their current place in the therapy of cardiovascular diseases. Circulation 22 (1960), 1156–1165.
40. Griffith, G.C., The importance of the monoamine oxidase inhibitors in cardiovascular disease. Am. J. Cardiol. 6 (1960), 1103–1105.
41. Emory, H., Mizrahi, N., Glycaemic control by monoamine oxidase inhibition in a patient with type 1 diabetes. Diabetes Vasc. Dis. Res. 14:2 (2016), 163–165.
42. Binda, C., Aldeco, M., Geldenhuys, W.J., Tortorici, M., Mattevi, A., Edmondson, D.E., Molecular insights into human monoamine oxidase B inhibition by the glitazone anti-diabetes drugs. ACS Med. Chem. Lett. 3 (2011), 39–42.
43. Alkhouli, M., Mathur, M., Patil, P., Revisiting the “cheese reaction”: more than just a hypertensive crisis?. J. Clin. Psychopharmacol. 34 (2014), 665–667.
44. Ngo, A.S., Ho, R.Y., Olson, K.R., Phenelzine-induced myocardial injury: a case report. J. Med. Toxicol. 6 (2010), 431–434.
45. Bonnet, U., Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 9 (2003), 97–140.
46. Youdim, M.B., Weinstock, M., Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25 (2004), 243–250.
47. van Haelst, I.M., van Klei, W.A., Doodeman, H.J., Kalkman, C.J., Egberts, T.C., Group, M.S., Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study. J. Clin. Psychiatry 73 (2012), 1103–1109.